Cited by

• Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.

  Yang S, Zhan J, Xu X. Yang S, et al. Endocrine. 2023 Dec;82(3):491-497. doi: 10.1007/s12020-023-03507-3. Epub 2023 Sep 13. Endocrine. 2023. PMID: 37702900 Review.
• Survival After Implementation of a Decision Support Tool to Facilitate Evidence-Based Cancer Treatment.

  Ojha RP, Lu Y, Narra K, Meadows RJ, Gehr AW, Mantilla E, Ghabach B. Ojha RP, et al. JCO Clin Cancer Inform. 2023 Jun;7:e2300001. doi: 10.1200/CCI.23.00001. JCO Clin Cancer Inform. 2023. PMID: 37343196
• Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.

  Courtinard C, Gourgou S, Jacot W, Carton M, Guérin O, Vacher L, Bertaut A, Le Deley MC, Pérol D, Marino P, Levy C, Uwer L, Perrocheau G, Schiappa R, Bachelot F, Parent D, Breton M, Petit T, Filleron T, Loeb A, Pélissier SM, Robain M, Delaloge S, Bellera C. Courtinard C, et al. BMC Med. 2023 Mar 8;21(1):87. doi: 10.1186/s12916-023-02754-5. BMC Med. 2023. PMID: 36882736 Free PMC article.
• Highlights from Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th-18th September, Mumbai, India.

  Akhade A, Gyawali B, Sullivan R, Sirohi B. Akhade A, et al. Ecancermedicalscience. 2022 Nov 3;16:1465. doi: 10.3332/ecancer.2022.1465. eCollection 2022. Ecancermedicalscience. 2022. PMID: 36819800 Free PMC article.
• Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.

  Cui W, Phillips KA, Anderson RA, Francis PA, Loi S, Loibl S, Partridge AH, Keogh LA. Cui W, et al. Am J Cancer Res. 2022 Dec 15;12(12):5599-5612. eCollection 2022. Am J Cancer Res. 2022. PMID: 36628283 Free PMC article.